After taking office, newly appointed CEO (president) Hwang Sang-yeon of Hanmi Pharmaceutical signaled a commitment to communication-focused management by visiting a manufacturing site as the first item on the official schedule and meeting with employees.
On the 2nd, Hanmi Pharmaceutical said Hwang visited the Hanmi Pharmaceutical R&D Center in Dongtan, Gyeonggi Province, after touring production plants in Paltan and Pyeongtaek in Gyeonggi Province the previous day, where Hwang inspected production lines and listened directly to voices from the research floor.
According to the company, Hwang first visited the Paltan business sites and greeted employees. Hwang then personally reviewed the pharmaceutical process based on advanced information and communications technology (ICT) and the logistics and delivery system using RFID, and listened to the on-site working-level staff's know-how.
The Pyeongtaek bioplant, a biopharmaceutical production base visited afterward, is equipped with large-scale manufacturing facilities of up to 12,500 liters and production lines capable of manufacturing more than 24 million prefilled syringes annually. Hwang said, "I gained deep trust and inspiration from the expertise of the on-site employees in a production process that tolerates not even the slightest error, and from Hanmi's pharmaceutical manufacturing capabilities."
A roundtable with researchers at the Dongtan R&D Center was also held. Hwang was said to have taken detailed notes on what support is needed to create the optimal environment for researchers to focus on developing innovative new drugs, and pledged to secure sustainable development momentum for various new drug development projects.
Hwang conveyed to employees a determination to uphold the management philosophy of "respect for humanity, value creation" of Hanmi Group founder and late chairman Lim Sung-ki, and to continue research and development (R&D) and quality management.